ArticleJournal for immunotherapy of cancer2025

Combinatorial treatment with upadacitinib abrogates systemic toxicity of a tumor-targeted IL-2 fusion protein.

Giulia Rotta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.